Roic.ailogo
Powered by AI
US stock · Healthcare sector · Biotechnology
Company Logo

CTI BioPharma Corp.

CTICNASDAQ

4.30

USD
- -
(- -)
Market Closed
-4.43P/E
10Forward P/E
-0.21P/E to S&P500
566.895MMarket CAP
- -Div Yield
SummaryFinancialsTranscriptsMonitoringClassic View
Upcoming Earnings
10 May-15 May
Shares Short
2/28/23
13.5M
Short % of Float
11.01%
Short % of Shares Outs.
10.24%
% Held by Insiders
0.19%
% Held by Institutions
81.83%
Beta
0.92
PEG Ratio
- -
52w. high/low
7.80/3.32
Avg. Daily Volume
2.92M
Return %
Stock
S&P 500
1 year
3.71
(9.05)
3 years
425.88
50.26
5 years
10.64
38.50
Scale: |
High
Low
5970.00
36.00
669.00
15.00
420.00
36.00
166.44
47.50
82.50
11.40
21.70
9.70
42.50
19.90
29.40
8.00
13.20
2.51
6.48
2.45
5.36
0.60
1.93
0.63
4.03
0.62
4.13
1.43
7.80
1.82
6.08
4.34
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
8.41
118.40
0.05
0.14
- -
- -
3.04
4.04
0.57
2.05
0.69
0.47
0.06
- -
- -
0.47
Earnings per share
(9,148.04)
(1,864.50)
(62.44)
(36.21)
(18.18)
(17.44)
(3.74)
(6.29)
(4.26)
(1.86)
(1.12)
(0.52)
(0.69)
(0.74)
(1.09)
(0.81)
FCF per share
(6,979.60)
(850.46)
(58.69)
(28.54)
(18.42)
(11.31)
(3.28)
(2.69)
(3.40)
(2.75)
(1.08)
(0.71)
(0.48)
(0.59)
(0.94)
(0.71)
Dividends per share
- -
195.30
2.04
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
116.12
19.78
0.97
0.88
0.79
0.51
0.15
0.02
0.00
0.00
0.00
0.00
- -
0.00
- -
- -
Book Value per sh.
(7,146.39)
(1,280.69)
(12.15)
(2.08)
8.37
5.94
3.96
2.81
1.86
0.48
0.60
1.05
0.41
0.56
0.04
(0.15)
Comm.Shares outs.
0
0
2
2
3
6
11
15
28
28
36
56
58
71
90
115
Avg. annual P/E ratio
(1.5)
(1.0)
(4.7)
(4.6)
(4.6)
(2.3)
(3.7)
(4.5)
(4.3)
(2.8)
(3.4)
(5.8)
(1.4)
(2.4)
(2.5)
(6.0)
P/E to S&P500
(0.1)
(0.0)
(0.1)
(0.2)
(0.3)
(0.2)
(0.2)
(0.2)
(0.2)
(0.1)
(0.1)
(0.2)
(0.1)
(0.1)
(0.1)
(0.3)
Avg. annual div. yield
- -
11.0%
0.7%
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
0
11
0
0
- -
- -
35
60
16
57
25
26
3
- -
- -
54
Operating margin
(104,713.4)%
(676.0)%
(101,948.8)%
(23,434.2)%
(Infinity)%
(Infinity)%
(119.7)%
(143.5)%
(723.9)%
(85.6)%
(157.2)%
(125.1)%
(1,217.1)%
(Infinity)%
(Infinity)%
(147.9)%
Depreciation (m)
5
5
2
2
2
2
2
1
1
1
1
1
1
1
1
2
Net profit (m)
(138)
(180)
(95)
(83)
(62)
(101)
(43)
(93)
(119)
(52)
(41)
(29)
(40)
(52)
(98)
(93)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net profit margin
(108,746.5)%
(1,574.8)%
(119,243.8)%
(25,906.6)%
(Infinity)%
(Infinity)%
(123.3)%
(155.4)%
(741.0)%
(90.6)%
(161.7)%
(111.5)%
(1,196.4)%
(Infinity)%
(Infinity)%
(172.4)%
Working capital (m)
(31)
(14)
(22)
(14)
33
38
60
44
63
15
28
59
17
37
2
18
Long-term debt (m)
127
145
24
4
- -
- -
10
8
19
11
14
9
7
1
2
- -
Equity (m)
(108)
(124)
(19)
(5)
29
35
45
42
52
13
22
59
24
40
4
(18)
ROIC
- -
- -
- -
- -
(135.8)%
(192.4)%
(54.2)%
(153.1)%
(152.8)%
(171.0)%
(93.4)%
(38.0)%
(114.7)%
(124.8)%
(1,650.6)%
(178.3)%
Return on capital
(167.7)%
(266.9)%
(129.8)%
(148.7)%
(97.4)%
(134.5)%
(42.9)%
(94.9)%
(78.5)%
(70.9)%
(63.7)%
(28.9)%
(74.0)%
(88.3)%
(131.8)%
(63.4)%
Return on equity
128.0%
145.6%
513.9%
1,741.3%
(217.2)%
(293.4)%
(94.6)%
(223.6)%
(229.5)%
(390.5)%
(186.4)%
(50.0)%
(168.9)%
(131.0)%
(2,599.1)%
529.1%
Plowback ratio
100.0%
110.5%
103.3%
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
6 Mar · 2023 | Q4
All numbers in millions
Total liabilities
$ 144
Total assets
$ 126
Long-term debt
$ - -
Cash and equiv.
$ 30
Goodwill
$ - -
Retained earnings
$ (2,519)
Common stock
115
Enterprise Value
$ 536
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
52
65
80
Receivables
- -
- -
15
Inventory
- -
- -
1
Other
2
28
(7)
Current assets
54
68
99
Acc. Payable
2
4
2
Debt due
4
49
48
Other
11
14
31
Current liabilities
17
67
81
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
- -
- -
- -
Cash flow
(4.35)%
29.57%
21.86%
Earnings
(5.02)%
37.30%
21.04%
Dividends
- -
- -
- -
Book value
(566.60)%
(161.96)%
(52.48)%
Insider Trading
Type
Shares
Date
Craig Adam R
Exempt
2,117
01/24/23
Craig Adam R
Exempt
83,200
01/24/23
Craig Adam R
Exempt
2,117
01/24/23
Craig Adam R
Sale
2,117
01/24/23
Craig Adam R
Exempt
83,200
01/24/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
2
12
18
21
54
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(0.17)
(0.20)
(0.16)
(0.21)
(0.74)
2021
(0.19)
(0.22)
(0.27)
(0.41)
(1.09)
2022
(0.32)
(0.20)
(0.14)
(0.15)
(0.81)
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Dr. Adam R. Craig M.B.A., M.D., Ph.D.
Full-time employees:
121
City:
Seattle
Address:
3101 Western Avenue
IPO:
Mar 21, 1997
CIK:
0000891293
Website:
ctibiopharma.com
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.